Technology transfer / Localization · GCC · Announced 22 Oct 2026
Abbott → Mubadala Bio
Technology transfer / Localization deal between Abbott (United States) and Mubadala Bio (United Arab Emirates), announced 22 Oct 2026.
Parties: Abbott (United States) → Mubadala Bio (United Arab Emirates)
- Deal type
- Technology transfer / Localization
- Value
- Not stated
- Territory
- AE (manufacturing); distribution scope wider
- Therapeutic area
- Women's Health
- Asset
- ocal manufacturing agreement for women's health therapies + expanded collaboration across distribution and other healthcare areas
- Announced
- 22 Oct 2026
Our analysis
Why this matters
This is the fourth Mubadala Bio partnership in one week — and the most structurally revealing.
Abbott ,in June 2025 it signed a four-pillar framework with the Department of Health – Abu Dhabi (portfolio localization, biosimilar development, digital patient leaflets, workforce development), with Mubadala Bio formally part of the official Abu Dhabi delegation.
The full analysis is free to read with a work email on this page.